Options with increasing volume: NYMX MYL ULTA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Mylan (MYL) Plans to Launch Generic EpiPen; Will Cost 50% Less than Name Brand
August 29, 2016 6:06 AM EDTMylan N.V. (Nasdaq: MYL) announced that its U.S. subsidiary will launch the first generic to EpiPen Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, or wholesale acquisition cost ("WAC"), of the branded medicine. The authorized generic will be identical to the branded product, including device functionality and drug formulation. Mylan expects to launch the product in several weeks, pending completion of labeling revisions. Upon launch, the product will be available as a two-pack carton... More
Mylan's (MYL) EpiPen Saga Could Add More Supply Chain Volatility Moving Forward - Evercore
August 25, 2016 11:46 AM EDTEvercore ISI affirms Mylan (Nasdaq: MYL) with a Hold rating and $49 price target amid today's EpiPen cost-adjustment news.
The firm commented, Thanks to our top rated Specialty Pharma guru Umer Raffat (and CNBC) we are highlighting a slide Mylan is featuring (see below) in its... More
